PDF herunterladen
Semin Reprod Med 2009; 27(4): 299-305
DOI: 10.1055/s-0029-1225257
© Thieme Medical Publishers

Characterizing Cardiovascular Risk in Women with Polycystic Ovary Syndrome: More than the Sum of Its Parts?

Alice Y. Chang1 , 2 , Robert A. Wild3
  • 1Departments of Internal Medicine and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
  • 2Division of Endocrinology and Metabolism, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma
  • 3Departments of Obstetrics and Gynecology, Medicine, Biostatistics and Epidemiology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Juni 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS), a condition of irregular menses and androgen excess, is the most common endocrinopathy of young women. Insulin resistance is a well-established feature among many women with PCOS, even in the nonobese. Therefore, it is not surprising that PCOS is frequently associated with cardiovascular risk factors and the metabolic syndrome. However, it is not known whether PCOS is an independent risk factor for atherosclerosis and cardiovascular (CV) events or whether CV risk is attributable to associated risk factors. We review previous studies on CV risk and disease in women with PCOS, describing the pitfalls and challenges in ascribing CV risk to PCOS. Women with PCOS might be partly reassured that their relative risk approximates that of the metabolic syndrome (RR 1.5) and also strongly counseled at the individual level about the greatest potential threat to their CV health, the development of type 2 diabetes.

KEYWORDS

Androgen excess - insulin resistance - metabolic syndrome - cardiovascular disease - type 2 diabetes

REFERENCES

  • 1 Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population.  J Clin Endocrinol Metab. 2004;  89 2745-2749
    CrossrefPubMedGoogle Scholar
  • 2 Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.  Fertil Steril. 2006;  86(Suppl 1) S7-S8
    PubMedGoogle Scholar
  • 3 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab. 1998;  83 3078-3082
    CrossrefPubMedGoogle Scholar
  • 4 Barber T M, Wass J A, McCarthy M I, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.  Clin Endocrinol (Oxf). 2007;  66 513-517
    PubMedGoogle Scholar
  • 5 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-1174
    CrossrefPubMedGoogle Scholar
  • 6 Hollinrake E, Abreu A, Maifeld M, Van Voorhis B J, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome.  Fertil Steril. 2007;  87 1369-1376
    CrossrefPubMedGoogle Scholar
  • 7 Glassman A H. Depression and cardiovascular comorbidity.  Dialogues Clin Neurosci. 2007;  9 9-17
    PubMedGoogle Scholar
  • 8 Tasali E, Van Cauter E, Hoffman L, Ehrmann D A. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2008;  93 3878-3884
    CrossrefPubMedGoogle Scholar
  • 9 Vgontzas A N, Legro R S, Bixler E O, Grayev A, Kales A, Chrousos G P. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.  J Clin Endocrinol Metab. 2001;  86 517-520
    CrossrefPubMedGoogle Scholar
  • 10 Parati G, Lombardi C, Narkiewicz K. Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk.  Am J Physiol Regul Integr Comp Physiol. 2007;  293 R1671-R1683
    PubMedGoogle Scholar
  • 11 Dahlgren E, Janson P O, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.  Acta Obstet Gynecol Scand. 1992;  71 599-604
    CrossrefPubMedGoogle Scholar
  • 12 Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.  Hum Fertil (Camb). 2000;  3 101-105
    CrossrefPubMedGoogle Scholar
  • 13 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.  Clin Endocrinol (Oxf). 2000;  52 595-600
    Google Scholar
  • 14 Pierpoint T, McKeigue P M, Isaacs A J, Wild S H, Jacobs H S. Mortality of women with polycystic ovary syndrome at long-term follow-up.  J Clin Epidemiol. 1998;  51 581-586
    CrossrefPubMedGoogle Scholar
  • 15 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
    CrossrefPubMedGoogle Scholar
  • 16 Reindollar R H, Novak M, Tho S P, McDonough P G. Adult-onset amenorrhea: a study of 262 patients.  Am J Obstet Gynecol. 1986;  155 531-543
    PubMedGoogle Scholar
  • 17 Solomon C G, Hu F B, Dunaif A et al.. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.  JAMA. 2001;  286 2421-2426
    CrossrefPubMedGoogle Scholar
  • 18 Malik S, Wong N D, Franklin S S et al.. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.  Circulation. 2004;  110 1245-1250
    CrossrefPubMedGoogle Scholar
  • 19 Rutter M K, Meigs J B, Sullivan L M, D'Agostino Sr R B, Wilson P W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.  Circulation. 2004;  110 380-385
    CrossrefPubMedGoogle Scholar
  • 20 Wild R A, Grubb B, Hartz A, Van Nort J J, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease.  Fertil Steril. 1990;  54 255-259
    PubMedGoogle Scholar
  • 21 Krentz A J, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease.  Menopause. 2007;  14 284-292
    CrossrefPubMedGoogle Scholar
  • 22 Shaw L J, Bairey Merz C N, Azziz R et al.. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.  J Clin Endocrinol Metab. 2008;  93 1276-1284
    CrossrefPubMedGoogle Scholar
  • 23 Spencer J B, Klein M, Kumar A, Azziz R. The age-associated decline of androgens in reproductive age and menopausal black and white women.  J Clin Endocrinol Metab. 2007;  92 4730-4733
    CrossrefPubMedGoogle Scholar
  • 24 Winters S J, Talbott E, Guzick D S, Zborowski J, McHugh K P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome.  Fertil Steril. 2000;  73 724-729
    CrossrefPubMedGoogle Scholar
  • 25 Loucks T L, Talbott E O, McHugh K P, Keelan M, Berga S L, Guzick D S. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?.  Fertil Steril. 2000;  74 547-552
    CrossrefPubMedGoogle Scholar
  • 26 Rumberger J A, Simons D B, Fitzpatrick L A, Sheedy P F, Schwartz R S. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study.  Circulation. 1995;  92 2157-2162
    CrossrefPubMedGoogle Scholar
  • 27 Schmermund A, Baumgart D, Görge G et al.. Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity.  J Am Coll Cardiol. 1998;  31 1267-1273
    CrossrefPubMedGoogle Scholar
  • 28 Lorenz M W, Markus H S, Bots M L, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis.  Circulation. 2007;  115 459-467
    CrossrefPubMedGoogle Scholar
  • 29 Gokce N, Keaney Jr J F, Hunter L M et al.. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.  J Am Coll Cardiol. 2003;  41 1769-1775
    CrossrefPubMedGoogle Scholar
  • 30 Loria C M, Liu K, Lewis C E et al.. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study.  J Am Coll Cardiol. 2007;  49 2013-2020
    CrossrefPubMedGoogle Scholar
  • 31 Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy II P F, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 2562-2568
    CrossrefPubMedGoogle Scholar
  • 32 Shroff R, Kerchner A, Maifeld M, Van Beek E J, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.  J Clin Endocrinol Metab. 2007;  92 4609-4614
    CrossrefPubMedGoogle Scholar
  • 33 Talbott E O, Zborowski J V, Rager J R, Boudreaux M Y, Edmundowicz D A, Guzick D S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 5454-5461
    CrossrefPubMedGoogle Scholar
  • 34 Jain T, Peshock R, McGuire D K Dallas Heart Study Investigators et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study.  J Am Coll Cardiol. 2004;  44 1011-1017
    CrossrefPubMedGoogle Scholar
  • 35 Talbott E O, Guzick D S, Sutton-Tyrrell K et al.. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol. 2000;  20 2414-2421
    PubMedGoogle Scholar
  • 36 Orio Jr F, Palomba S, Cascella T et al.. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 4588-4593
    CrossrefPubMedGoogle Scholar
  • 37 Carmina E, Orio F, Palomba S et al.. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.  Am J Med. 2006;  119 351.e1-6
    PubMedGoogle Scholar
  • 38 Vryonidou A, Papatheodorou A, Tavridou A et al.. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 2740-2746
    CrossrefPubMedGoogle Scholar
  • 39 Meyer C, McGrath B P, Cameron J, Kotsopoulos D, Teede H J. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 4630-4635
    CrossrefPubMedGoogle Scholar
  • 40 Talbott E O, Zborowski J V, Boudreaux M Y, McHugh-Pemu K P, Sutton-Tyrrell K, Guzick D S. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 6061-6067
    CrossrefPubMedGoogle Scholar
  • 41 Meyer C, McGrath B P, Teede H J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.  J Clin Endocrinol Metab. 2005;  90 5711-5716
    CrossrefPubMedGoogle Scholar
  • 42 Tarkun I, Arslan B C, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.  J Clin Endocrinol Metab. 2004;  89 5592-5596
    CrossrefPubMedGoogle Scholar
  • 43 Dokras A, Jagasia D H, Maifeld M, Sinkey C A, VanVoorhis B J, Haynes W G. Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome.  Fertil Steril. 2006;  86 1702-1709
    CrossrefPubMedGoogle Scholar
  • 44 Lakhani K, Leonard A, Seifalian A M, Hardiman P. Microvascular dysfunction in women with polycystic ovary syndrome.  Hum Reprod. 2005;  20 3219-3224
    CrossrefPubMedGoogle Scholar
  • 45 Paradisi G, Steinberg H O, Hempfling A et al.. Polycystic ovary syndrome is associated with endothelial dysfunction.  Circulation. 2001;  103 1410-1415
    CrossrefPubMedGoogle Scholar
  • 46 Rosamond W, Flegal K, Friday G American Heart Association Statistics Committee and Stroke Statistics Subcommittee et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Circulation. 2007;  115 e69-e171
    CrossrefPubMedGoogle Scholar
  • 47 Kardys I, Vliegenthart R, Oudkerk M, Hofman A, Witteman J C. The female advantage in cardiovascular disease: do vascular beds contribute equally?.  Am J Epidemiol. 2007;  166 403-412
    CrossrefPubMedGoogle Scholar
  • 48 Haffner S M, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
    CrossrefPubMedGoogle Scholar
  • 49 Grundy S M, Howard B, Smith Jr S, Eckel R, Redberg R, Bonow R O. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association.  Circulation. 2002;  105 2231-2239
    CrossrefPubMedGoogle Scholar
  • 50 Schramm T K, Gislason G H, Køber L et al.. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.  Circulation. 2008;  117 1945-1954
    CrossrefPubMedGoogle Scholar
  • 51 Sowers J R. Diabetes mellitus and cardiovascular disease in women.  Arch Intern Med. 1998;  158 617-621
    CrossrefPubMedGoogle Scholar
  • 52 Gregg E W, Gu Q, Cheng Y J, Narayan K M, Cowie C C. Mortality trends in men and women with diabetes, 1971 to 2000.  Ann Intern Med. 2007;  147 149-155
    CrossrefPubMedGoogle Scholar
  • 53 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 54 Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.  Diabetes Care. 1999;  22 141-146
    CrossrefPubMedGoogle Scholar
  • 55 Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.  J Clin Endocrinol Metab. 2005;  90 3236-3242
    CrossrefPubMedGoogle Scholar
  • 56 Boudreaux M Y, Talbott E O, Kip K E, Brooks M M, Witchel S F. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up.  Curr Diab Rep. 2006;  6 77-83
    CrossrefPubMedGoogle Scholar
  • 57 Norman R J, Masters L, Milner C R, Wang J X, Davies M J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 1995-1998
    CrossrefPubMedGoogle Scholar
  • 58 Saad M F, Knowler W C, Pettitt D J, Nelson R G, Mott D M, Bennett P H. The natural history of impaired glucose tolerance in the Pima Indians.  N Engl J Med. 1988;  319 1500-1506
    PubMedGoogle Scholar
  • 59 Kim C, Newton K M, Knopp R H. Gestational diabetes and the incidence of type 2 diabetes: a systematic review.  Diabetes Care. 2002;  25 1862-1868
    CrossrefPubMedGoogle Scholar

Alice Y ChangM.D. M.S. 

University of Texas Southwestern Medical School

MC 8857, 5323 Harry Hines Blvd., Dallas, TX 75390-8857

eMail: alice.chang@utsouthwestern.edu

      >